Trials / Completed
CompletedNCT05421091
Special Drug Use-results Surveillance of Scemblix Tablets
Special Drug Use-results Surveillance of Scemblix Tablets (Resistant or Intolerant Chronic Myeloid Leukemia , CABL001A1401)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 550 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 99 Years
- Healthy volunteers
- Not accepted
Summary
Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.
Detailed description
The objective of this study is to collect data on the occurrence, severity, clinical courses of the safety specifications of asciminib, identify factors etc. involved in occurrence and assess its clinical safety inresistant/intolerant chronic myelogenous leukemia patients during an observational period of 48 weeks from the start of treatment with asciminib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Asciminib | Prospective observational study. There is no treatment allocation. Patients prescribed with asciminib are eligible to enroll into this study. |
Timeline
- Start date
- 2022-07-04
- Primary completion
- 2024-02-29
- Completion
- 2024-02-29
- First posted
- 2022-06-16
- Last updated
- 2024-03-27
Locations
278 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT05421091. Inclusion in this directory is not an endorsement.